Media

Newsroom

Back to news

Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease

June 9, 2016

9 June 2016 (Lausanne, Switzerland) – Galderma today announced that its trifarotene development program targeting lamellar ichthyosis, a debilitating orphan disease resulting in the formation of scales covering the skin, was demonstrated to be safe and well-tolerated in a phase I study.  Trifarotene is a first-in-class molecule being developed by Galderma, the medical solutions business of Nestlé Skin Health.

“We are pleased to see the results of this study support the continued development of trifarotene which has the potential to provide a new solution to the needs of patients suffering from lamellar ichthyosis,” says Thibaud Portal, Ph.D., Vice President of Galderma's prescription business.  “We are dedicated to meeting the needs of all patients with skin diseases over the course of their lives and trifarotene has been designed to meet the safety profile that patients with lamellar ichtyosis need.” 

Read the full press release on Galderma.com

Back to top